Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Retatrutide in the phase 2 trial hit 24.2% at the highest dose over 48 weeks
Eligibility is determined through a licensed providers evaluation
A phase I, pharmacokinetic and pharmacodynamic study of weekly MK-0646, an insulin-like growth factor-1 receptor monoclonal antibody in patients with advanced solid tumors
Early attention, sensible lifestyle changes, and modern diagnostic tools can identify the cause and guide effective treatment
This triple mechanism of action distinguishes retatrutide from existing approved therapies, which typically act on one or two of these pathways
Semax received a favorable 851 vote Semax free base and Semax acetate were the final substances considered
US$ 25.16
US$ 20.71
US$ 26.18
US$ 20.34
US$ 22.20
US$ 22.77
US$ 25.72
